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Increasing evidence implicates brain-derived neurotrophic factor
(BDNF) in depression.1 Brain-derived neurotrophic factor is
essential for the developing brain, and plays a major role in
plasticity of the adult brain.2,3 Antidepressant drugs, such as
fluoxetine, increase levels of BDNF mRNA in the hippo-
campus.4–7 Blocking BDNF also prevents their action on rodent
behaviours in experimental ‘models’ of depression.8 The same
drugs stimulate mitotic activity of the progenitor cells in the adult
hippocampus of the rat, and this also depends on BDNF.9,10 The
parallels between factors that alleviate depression and those that
increase hippocampal neurogenesis have led to the suggestion that
the two are linked.11,12
Plasma levels of BDNF are lowered in depression, and increase
with recovery, although how blood levels of BDNF relate to those
in the brain is uncertain.13–15 Since depression is a frequent and
moderately heritable disorder, common genetic variants are
likely to contribute to its pathogenesis. A common variant at
the Val/66/Met locus (rs6265) of the BDNF gene with the minor
Met allele carried by 30% humans is associated with reduced
activity-dependent secretion of BDNF, and altered processing of
pro-BDNF to the mature molecule.16 Attempts to show a simple
association between one or other BDNF variants and the
occurrence of depression have not been consistent.17–19 A more
promising approach has followed the recognition that genetic
variants (for example in the serotonin transporter) may interact
with elements in the environment, such as early or more proximal
adversity, to determine the risk for depression,20 although some
aspects of such studies remain controversial.21–24 A similar
approach has been adopted with the BDNF Val/66/Met variant;
two studies have reported an interaction between the Met allele
and life events in predicting major depressive disorder.25,26 The
association between adversity (maltreatment) during early life
and subsequent depression is accentuated in those with the Met
allele.27–29
A less explored avenue is whether genetic variants may also
interact with endogenous factors, such as cortisol. Damped
diurnal rhythms of cortisol are well-established to occur in a
proportion of cases of major depression,30 as does resistance to
the normal negative feedback effect of administered gluco-
corticoids.31,32 Furthermore, both adolescents and adult women
with levels of cortisol in the morning in the upper normal
range are at higher risk of subsequent depression.33,34 Levels of
morning salivary cortisol have been reported to interact with
the BDNF Val/66/Val genotype (not the Met allele) to predict first
onset depression in adolescents.35 A three-way association
between life events, this BDNF variant and cortisol levels has
not been found so far. The hypothesis explored in this paper is
whether the Val or Met allele of the BDNF Val/66/Met variant is
associated with morning cortisol levels as a predictor of the onset
of a depressive episode in adult women; and, in particular,
whether there is an interaction between the two measures. We
examined three samples of participants, collected in the same
way and according to the same criteria, but separated both by time
of sampling and by domicile. In this way, we hoped to establish a
more general pattern of risk in adult women than is usually the
case.
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Background
Common genetic variants, such as the brain-derived
neurotrophic factor (BDNF) Val/66/Met polymorphism
(rs6265), are known to interact with environmental factors
such as early adversity to increase the risk of subsequent
major depression. Much less is known about how they
interact with individual differences in cortisol, although these
also represent a risk for major depression.
Aims
To determine whether this BDNF variant moderated the risk
represented by higher levels of morning salivary cortisol in
adult women.
Method
We recruited 279 premenopausal women who were at high
risk of major depressive disorder because of either negative
self-evaluation, unsupportive core relationship or chronic
subclinical symptoms of depression or anxiety. Morning
salivary cortisol was measured daily for up to 10 days at
entry. Participants were followed up for about 12 months by
telephone calls at 3–4 monthly intervals. Major depression
and severe life events were assessed through interviews at
baseline and follow-up; DNA was obtained from the saliva.
Results
There were 53 onsets (19%) of depressive episodes during
follow-up. There was a significant U-shaped relationship
between adjusted morning cortisol levels at baseline and the
probability of depression onset during follow-up. In total, 51%
experienced at least one severe life event/difficulty, and this
strongly predicted subsequent onsets of depressive episodes.
The BDNF Val/66/Met genotype was not directly associated
with onsets of depression or with cortisol levels, but there
was significant interaction between Val/66/Met and cortisol:
the association between baseline cortisol and depression
was limited to those with the Val/66/Val variant. There was
no interaction between life events and either this BDNF
polymorphism or cortisol levels.
Conclusions
Morning salivary cortisol interacts with the BDNF Val/66/Met
polymorphism in predicting new depressive episodes. This
paper adds to the evidence that single gene polymorphisms
interact with endogenous factors to predict depression.
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Method
Samples
The study population consisted of three samples. The participants
in each sample were recruited in the same way, assessed at entry in
a similar manner (with some minor differences, described below)
and followed up in the same way for 12–18 months. Participants
were premenopausal (except that sample 1 included women aged
up to 66) were of European (White) descent and had at least one
child. The levels of cortisol and its association with the prospective
onset of major depressive disorder (but not the interaction with
BDNF Val/66/Met) in sample 1 have already been reported.33
Recruitment
The location and date of each sample was as follows.
(a) Sample 1: Islington, Inner City of North London, 1996–1999,
n= 116, of whom 44 consented in 2004 to give further saliva
for genotyping for this analysis.
(b) Sample 2: Southwark & Lambeth, Inner City of South London,
2003–2006, n=155.
(c) Sample 3: Oxford, 2003–2006, n= 80.
General practitioners in each area agreed to circulate all
women in the relevant age group registered with their practice
with a questionnaire as a preliminary to participating in some
research about the health of women and their circumstances.
Depression was not explicitly mentioned. They explained that they
thought the research was worthwhile and hoped the recipients
would find time to fill in the form and return it in a stamped
addressed/freepost envelope to the research team’s address giving
their contact details if they were willing to participate further.
Across the three areas some 7000 such forms were mailed out,
of which 2388 were returned, in line with previous surveys of
primary care lists, which often contain 30% names of persons
who have moved on. The form contained information about
current mental state, self-esteem and core relationship quality that
would allow the identification of women who were not currently
experiencing clinical depression but who were considered
vulnerable through at least one of these three characteristics found
from previous work to predict onset within the short term:
(a) negative evaluation of self
(b) negative elements in core relationships
(c) chronic subclinical conditions of depression or anxiety.
Eligible women (n= 523) were then telephoned to confirm
eligibility. Women found to be vulnerable but, not currently
depressed or receiving corticoid medication, but with adequate
command of English were invited to take part. The procedures
involved (which included providing morning saliva samples and
tape-recorded interviews) were explained and a time arranged
for baseline interview in the individual’s house (or – if she pre-
ferred – at the research team’s office). This identified 160 women
not meeting inclusion criteria, 84 unwilling to take part and 279
eligible women willing to participate.
Psychological measures
At entry, participants were assessed with psychological and
psychiatric instruments, including the following. The Schedule
for Clinical Assessment in Neuropsychiatry (SCAN)36 was used
to establish current mental state. Telephone screening had already
excluded women with current clinical (or case-level) depression,
but classifying minor symptoms was necessary for establishing
the chronic ‘subclinical’ mood disorder component of the three-
fold vulnerability index.37 This component is referred to here as
‘chronic subclinical conditions’ of either depression, anxiety or
obsessional disorder, chronic in the sense of having lasted
continuously for at least 1 year.38 When the condition comprised
anxiety rather than depressed mood it could involve disorder at a
clinical as well as a subclinical level. Case-level depression was
defined as either major depression as specified by DSM-IV,39 –
or Bedford College case-level depression.40 The latter is based
on an algorithm derived from data on women, which can be
approximated by following a checklist. This comprises a
minimum of 2 weeks of depressed mood and at least four other
very slightly different key symptoms (key symptoms in the
DSM-IV list not included in the Bedford College list are social
withdrawal and pathological guilt, whereas a key symptom in
the latter list is preoccupational brooding). The Bedford College
criterion also defines high-, medium- and low-borderline
depressive conditions. The medium-borderline condition
specified for the classification of chronic subclinical conditions
requires depressed mood and two of the key symptoms. Those
with high-borderline case conditions (with three key symptoms)
are excluded from the chronic subclinical conditions category to
maximise clarity in rating a new onset later. Low-borderline case
depressions are not classified as being chronic subclinical
conditions nor are low-borderline case anxieties (only one phobic
object).
The Self Evaluation and Social Support Schedule (SESS)41 was
used to rate the second component of the vulnerability index.
Negative evaluation of core relationships involves a ‘marked’ or
‘moderate’ rating on a four-point scale of ‘negative interaction’
with a child living at home or, if married, in relation to her
husband or partner. Both take into account reports about arguing,
strain, violence and indifference, and ignoring anything positive
about a relationship. Single women are also included as scoring
positively on the negative evaluation of core relationships if they
have negative interaction with another close relative or household
member, or if they lack regular confiding contact with someone
they define as very close.
Negative evaluation of self, the third component of the
vulnerability index, involves low self-esteem as defined by a score
of ‘marked’ or ‘moderate’ on any of the three four-point scales
dealing with negative comments about (a) personal attributes,
such as intelligence, attractiveness and ability to get on with
people, (b) competence in roles, such as wife, mother, worker,
and (c) lack of self acceptance – more generalised feelings about
the way someone sees herself. In the Islington sample it was
measured at the time of first interview and was found to be
predictive of onset of depression.38
The Life Events and Difficulties Schedule (LEDS) employs
a semi-structured interview and is based on a system of
contextual measures reflecting the likely meaning of events and
difficulties.42,43 These are contrasted with self-report or
subjective ratings that record what the respondent actually felt
about the event – for example, how upsetting she found it. The
date of each event is recorded in terms of week of occurrence.
Severe events are defined as having a severe long-term threat
10–14 days after their occurrence based on a judgement that takes
into account relevant biographical and current circumstances, but
ignores any report of emotional response. The ratings are referred
to as ‘contextual’ because this procedure encompasses a much
broader range of material than mere details of the event itself.
Onset of depression has been linked with severe events occurring
in various time periods,42 but there is general agreement that
almost all of aetiological importance probably occur within
6 months of onset – usually within a matter of weeks.42 Severe
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long-term difficulties are ongoing problems such as cramped
housing or poor relationships that may not necessarily give rise
to events as defined but are rated on parallel scales of severity if
lasting 4 weeks or more.44 A combined index of ‘new provoking
agent’ used here identifies experience of either a new severe
difficulty or a severe event between baseline and follow-up.
Saliva samples and cortisol assay
Participants provided samples of saliva around 08.00 h and 20.00 h
over 4–10 days by drooling into a labelled tube within a week of
the interview. Each saliva sample was assayed separately. Mean
levels of cortisol were derived from each set. Cortisol was
measured by enzyme-linked immunosorbent assay (ELISA) on
20 ml samples of saliva without extraction (antibody Cambio
UK). Intra-assay variation was 5.1–5.7% and inter-assay variation
5.6–6.7% for each set of samples. Details of the assay are given
elsewhere.33 Levels are reported in ng/ml. Stages of the menstrual
cycle were not recorded, but were likely to be evenly distributed in
a sample of this size. There is no evidence that cortisol varies
predictably during the menstrual cycle.45 Moreover in sample 1
no differences had emerged according to the stage of menstrual
cycle.33
Genotyping
We harvested DNA from a separate sample of saliva (Oragene,
Canada), and genotyped for the Val/66/Met variant in rs6265 of
the BDNF gene by a commercial laboratory (Source Bioscience,
UK).
Follow-up
Participants were contacted by telephone at 3–4 monthly intervals
for about 12 months to monitor onset of depression or the
occurrence of life events. If onset had occurred, the final
follow-up interview took place in the participant’s home soon
afterwards. Otherwise, the final interview was carried out 12–14
months after the baseline interview. At this time crucial measures
of the SCAN and LEDS were repeated for the whole of the
intervening period.
Statistical analysis
We used binary regression to predict the risk of onset of a major
depressive episode during follow-up. There were no cases of
bipolar disorder. Mean morning cortisol, stressful life events and
BDNF genotype were the predictor variables of interest. Their
direct effect and two-way interactions were tested as significant
risk difference in binomial regression models, as previously
recommended.46
Mean morning cortisol was cleaned to remove outlier
measurements and adjusted for time of sampling before being
used as a predictor in the binary regressions (see below). Since
previous evidence suggested a U-shaped relationship between
cortisol and risk of depression,3 we have systematically tested both
linear and quadratic (curved) effects.
Results
Of the 279 women vulnerable to depression and willing to
participate, 58% had a negative evaluation of self, 52% chronic
subclinical conditions and 33% negative elements in core
relationships. The average age was 36.8 years.
Baseline salivary morning cortisol
We first examined the distribution of the baseline morning
cortisol values. Cortisol data were available for 279 women from
the three samples. In sample 1, cortisol levels were measured on
4 consecutive days in 44 women (average number of valid
measurements: 3.9). In samples 2 and 3, cortisol was measured
on 10 consecutive days; 155 women provided on average 9.3 valid
cortisol values. In sample 3, 80 women provided on average 9.1
valid levels. Across the three samples, a total of 2346 cortisol
measurements were available for the 279 women. To minimise
the effect of measurement inaccuracies and random factors
affecting the cortisol measures, we first checked the measured
cortisol values for outliers. Of the 2346 measurements, 15 were
two standard deviations or more below and 47 were two standard
deviations or more above the mean value of the remaining
measurements. These 62 measurements were considered outliers.
The remaining 2284 measurements were considered valid and
used for calculating individual means. Cortisol levels did not vary
with measurement day (1–0) (b=70.004, 95% CI 70.025 to
0.017, P=0.74). However, cortisol levels decreased significantly
with time of the day, approximately 0.38 ng/ml every hour
(b=70.390, 95% CI 70.505 to 70.275, P50.0001). Therefore,
we adjusted cortisol measurements for sampling time (using first
and second polynomial of time). The mean values for each
individual were calculated as arithmetic means of on average 8.2
(range 3–10) measurements adjusted for sampling time. Adjusted
cortisol levels did not differ by sample (F(2,276) = 2.25, P= 0.11)
and were nearly normally distributed with a slight right skew
(Fig. 1).
Onset of depression
There were 53 onsets of major depressive episodes (19% of the
total sample) during the study. Analysis of the three samples
individually showed that while sample 1 and 2 showed similar
incidences of onset (29.5% and 23.4% respectively), this was lower
in sample 3 (9.7%) (w2 = 7.22, P=0.027). Therefore, the study
sample was controlled for in all subsequent analyses. Onset was
unrelated to experience of a previous depressive episode or to
baseline chronic subclinical symptoms of either depression or
other conditions. Neither negative elements in core relationships
nor negative evaluation of self predicted the subsequent onset of
major depression in this data-set (logistic regression: P40.05 in
each case). Nor was there any association between morning
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Fig. 1 Distribution of average morning cortisol levels, adjusted
for sampling time.
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cortisol and any of the three vulnerability factors (chronic
subclinical symptoms, negative elements in core relationships,
negative evaluation of self). Association between a score conveying
the number of such factors experienced by each woman and
depressive onset, although clear among the whole data-set
(P= 0.038), just failed to reach statistical significance among those
participants with data on both cortisol and BDNF.
Morning cortisol levels and the onset of depression
Next, we asked whether individual differences in cortisol values
predicted the subsequent onset of an episode of major depression.
There was a significant U-shaped relationship between adjusted
morning cortisol levels at baseline and the probability of
depression onset during follow-up. This is shown in Fig 2. This
relationship was controlled for sample (i.e. sample 1, 2 or 3) as
a covariate. The risk difference per ng/ml cortisol was 0.028
(95% CI 0.011–0.045, P= 0.001). The odds ratio was 1.12 (95%
CI 1.01–1.21, P= 0.031). There was no significant interaction
between sample and mean adjusted morning cortisol in predicting
onset (P40.1).
New provoking agent, cortisol and onset
of depression
Many studies have shown that an adverse life event precedes major
depression, and we confirmed that this was the case in this study.
In total, 51% of the total sample experienced at least one severe
life event during follow-up. As expected, such an experience
strongly predicted subsequent onset of depression (risk difference:
0.254, 95% CI 0.159–0.349, P50.001). The occurrence of a severe
life event was independent of baseline levels of morning cortisol.
Adjusted mean cortisol levels did not significantly predict the
subsequent occurrence of a severe life event either linearly
(P= 0.1) or as a curved relationship (P= 0.1).
We then went on to examine whether such agents and cortisol
interacted to predict depression. There was no significant inter-
action between the curved cortisol function (quadratic) and a
severe life event in predicting depressive onsets (risk difference:
70.00092, 95% CI 70.01001 to 0.0082, P=0.842), whereas
severe life events and the mean adjusted baseline cortisol remained
significant predictors of depressive onset (Table 1).
Interaction between morning cortisol levels and BDNF
Val/66/Met in predicting onset of depression
We next examined the contribution of the common BDNF Val/66/
Met polymorphism as a predictor of the onset of an episode of
major depression. The BDNF rs6265 (Val/66/Met) genotypes in
this study were distributed as expected under Hardy–Weinberg
equilibrium (w2 = 0.157, P= 0.69), with a minor allele frequency
of 0.20. For subsequent analyses, we coded rs6265 under the
dominant Met allele genetic model, contrasting 88 Met allele
carriers with 157 Val allele homozygotes. Table 1 sets out these
analyses in detail.
The BDNF Val/66/Met genotype was not directly associated
with onsets of depression (risk difference: 0.049, 95% CI
70.067 to 0.164, P= 0.229) in this data-set, or with any of the
three vulnerability factors or their composite score. However,
there was a significant interaction between the quadratic cortisol
function and the BDNF Val/66/Met genotype in their effect on
depressive onsets under the additive statistical model (interaction
risk difference: 70.010, 95% CI 70.022 to 70.0001, P= 0.048)
(Table 1).
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Fig. 2 The relationship between cortisol level at baseline and
the risk of onset of a new depressive episode during the
follow-up based on the best fitting model estimates. The light
blue shading is the 95% confidence interval of these estimates.
Table 1 Results of multivariate binary regression models predicting new onsets of depression during follow-up
Risk difference (95% CI) z-score P
Interaction between mean adjusted 08.00 h cortisol and stressful life eventsa
Severe stressful life events 0.168 (0.099 to 0.237) 4.79 0.001
Cortisol: linear effect 70.164 (70.315 to70.0137) 72.14 0.032
Cortisol: quadratic effect 0.019 (0.000 to 0.039) 1.96 0.049
Interaction 70.001 (70.010 to 0.008) 70.20 0.842
Interaction between cortisol and BDNF genotype (binary: presence/absence of Met allele)b
Cortisol: linear effect 70.289 (70.464 to 70.115) 73.25 0.001
Cortisol: quadratic effect 0.033 (0.0108 to 0.055) 2.92 0.004
BDNF 0.031 (70.075 to 0.137) 0.57 0.565
Interaction (quadratic) 70.010 (70.021 to 0.000) 71.98 0.048
Analyses stratified by BDNF genotypesc
Val/Val homozygotes
Cortisol: linear effect 70.315 (70.553 to 70.079) 72.61 0.009
Cortisol: quadratic effect 0.042 (0.010 to 0.072) 2.62 0.009
Met carriers
Cortisol: linear effect 70.267 (70.524 to 70.009) 72.03 0.042
Cortisol: quadratic effect 0.025 (70.006 to 0.056) 1.57 0.115
a. Both stressful life events and mean adjusted cortisol are independent predictors of major depression onset.
b. BDNF genotype did not predict major depression, but there was a significant interaction with cortisol.
c. There are significant associations between cortisol and major depression in Val/Val genotypes, but not Met carriers. See text for further details.
BDNF gene, morning cortisol and depression
Further examination of these results showed that the
U-shaped relationship between the mean adjusted cortisol at
baseline and depressive onsets during the follow-up period was
limited to the Val/Val homozygotes but was not apparent in the
Met allele carriers. This is shown in Fig. 3 and Table 1. In Met
allele carriers, there was a weak (non-significant) negative linear
relationship with higher cortisol values being protective against
depression.
There was no significant interaction between BDNF Val/66/
Met and severe life events in predicting subsequent onset of
depression in this data-set (interaction risk difference: 70.139,
95% CI 70.068 to 0.345, P= 0.187).
Discussion
Main findings
Previous studies have shown that increasing levels of morning
cortisol, as measured in the saliva, are associated with increased
risk of depression.33,34 The results reported in this paper suggest,
in addition, that those with unusually low morning cortisol also
showed such an association; there was a quadratic relationship
between the hormone and the disorder. The occurrence of an
adverse life event is also a major predictor, but neither in this
study nor in previous ones on adolescents and adult women did
we find any association between salivary cortisol levels and life
events as interacting predictors of depression.33,34 However, it
should be noted that there is no information on the ways that
cortisol might alter in response to such life events, and hence play
a more proximal role in the likelihood of consequent depression.
We did not measure dehydroepiandrosterone, since our previous
studies have failed to show that this steroid is a risk factor for
major depression on its own, or that it interacts with BDNF.34,35,47
We found that the predictive value of morning salivary cortisol
depends on the BDNF rs6265 variant. In agreement with our
previous study on adolescents (in which we tested for a linear
function), higher levels of morning cortisol appear to represent
a risk factor for depression only in those carrying the BDNF
Val/66/Val variant.35 This replication strengthens the interpret-
ation that this association is a generalised risk factor, for there
are important differences between the two studies. Not only were
the adolescents younger than the participants studied here, but
their depressive episode was a first onset, whereas in this study,
many of the participants had had previous depressive episodes.
There have been a number of suggestions that antecedent factors
for first onset and recurrent episodes of depression might be
different.48 There were insufficient participants in this study for
us to determine whether the BDNF/cortisol interaction we
describe applied both to those with first and/or recurrent onsets.
Our findings, together with a previous report,35 suggest that
the BDNF Val/66/Met moderates the risk for major depression
represented by higher cortisol. It should be noted that we found
a quadratic relation between depressive onset and cortisol: as well
as higher cortisol predicting increased risk for depression in these
participants, there was some evidence that levels in the lower
range also represented increased risk. This needs to be confirmed
in a larger study, but it would not be unusual for hormones to
operate in an optimal range, and for departures in either direction
to have adverse consequences. It should also be noted that
previous studies20,25,26 (see introduction) have related the Met
BDNF allele to increased risk for major depression in some
contexts. However, it is plausible that one allele of a common
genetic variant may moderate one set of risk factors (for example,
psychosocial, such as early adversity in childhood or following
severe life events in adulthood23,26,27) but another allele may do
so in the context of a different one (for example levels of
hormones such as cortisol in adulthood). Differing vulnerabilities
according to circumstance have also been postulated for the
common s/l variant in the serotonin transporter, so that a given
polymorphism may be disadvantageous in one context, but
beneficial in another.49
Limitations
It is important to recognise that our study population was not a
single one, but made up of three separate samples collected from
different geographical areas (although within the same country)
and at different times (in one case). The size of each sample
was not sufficient for us to test whether the interaction we report
on the total sample might apply to each one individually.
Nevertheless, the fact that each was collected according to similar
criteria bolsters our contention that they can be considered
together. The only marked difference was that in one sample
(Oxford) the incidence of life events (and depression) was lower
than in the other two. Since we found no interaction between
the occurrence of life events and the BDNF variant when studied
as combined predictors of subsequent depression, we think that
this is not a significant problem with our data. However, to
confirm that results are not driven by any unmeasured differences,
we corrected for sample in all analyses.
The nature of the interaction
In studies that report an interaction between a genetic variation
and some physiological parameter (for example a steroid
hormone) in predicting a presumed dependent outcome (in this
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Fig. 3 The relationship between cortisol level at baseline and
the risk of onset of a new depressive episode during the
follow-up separately for BDNF rs6265 Val allele homozygotes
(a) and for Met allele carriers (b), based on the best fitting model
estimates. The light blue shading is the 95% confidence interval
of these estimates.
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case, depression), it is always important to exclude the possibility
that the genetic variant is associated with (and, maybe, responsible
for) individual differences in the measured parameter, in this case
cortisol. Since in this study, as in our previous one,35 we found no
direct association between BDNF rs6265 and individual values in
morning cortisol, we can exclude this possibility. It therefore
seems feasible that this variation in the BDNF gene and cortisol
may interact at a neural level to influence the risk for depression.
There is no direct neural evidence for such an interaction in
humans, largely because current techniques do not allow it to
be studied. But there is plentiful evidence from experimental
studies for an interaction between BDNF and glucocorticoids.
For example, excess corticosterone decreases the expression of
BDNF mRNA in the hippocampus.9,50 Excess corticoid also
interferes with the stimulating action of fluoxetine on hippo-
campal neurogenesis,51 although, as we point out earlier, the link
between hippocampal neurogenesis and depression is still
uncertain. Reduced hippocampal volumes have been reported
both in participants with current depression and those at high risk
of depression, although whether this relates directly to impaired
neurogenesis is still undetermined.52 Brain-derived neurotrophic
factor has a well-established role in promoting neural plasticity,
and this has been related both to the onset of depression and to
the therapeutic response to antidepressant drugs.1,2,53 In this
context, it is interesting that there is now experimental evidence
that fluoxetine also promotes neural plasticity,54 although whether
this is modulated by corticoids has not yet been reported. Since
corticoids reduce BDNF mRNA, it is reasonable to conclude
that the effect of BDNF on plasticity would also be reduced by
higher levels of cortisol. The BDNF Val/66/Met variant does not
occur naturally in rodents, although it can be produced artificially.
It will be interesting to see whether there are experimental
interactions between this variant and glucocorticoids that assist
the interpretation of the results we present in this paper.
In conclusion, the emerging consensus that the role of
particular genetic variants as risk factors for depression are best
studied as interactions with either environmental events or
physiological variables (‘endophenotypes’) is supported by the
data presented here. This paper reaffirms that individual
differences in cortisol, known to be a risk factor for depression,
are moderated by common variants in BDNF as well as other
genes.
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